

**AMENDMENTS TO THE CLAIMS**

1-14. **(Canceled)**

15. **(Currently Amended)** A method of treating type 2 diabetes or prophylactically suppressing type 2 diabetes in a mammal predisposed to type 2 diabetes, the method comprising administering to a mammal in need thereof a medicament comprising a sufficient amount of anakinra.
16. **(Previously Presented)** The method according to claim 15, wherein the medicament is adapted for parenteral administration.
17. **(Previously Presented)** The method according to claim 16, wherein anakinra is administered to the mammal in a dose of 0.1 to 1000mg of anakinra per kg of body weight.
18. **(Previously Presented)** The method according to claim 15, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).
19. **(Previously Presented)** The method according to claim 18, wherein the medicament is adapted for parenteral administration.
20. **(Previously Presented)** The method according to claim 19, wherein the anakinra is administered to the mammal in a dose of 0.1 to 1000mg of anakinra per kg of body weight.
21. **(Previously Presented)** The method according to claim 20, wherein the PDTC is administered to the mammal in a dose of 0.1 to 1000mg of PDTC per kg or body weight.
22. **(Previously Presented)** A method of treating type 2 diabetes, the method comprising administering to a mammal in need thereof a dose of 0.1 to 1000mg of anakinra per kg of body weight.

23. **(Previously Presented)** The method according to claim 22, wherein the medicament is administered via parenteral administration.
24. **(Previously Presented)** The method according to claim 22, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC).
25. **(Previously Presented)** The method according to claim 24, wherein the medicament is administered by parenteral administration.
26. **(Previously Presented)** The method according to claim 25, wherein the PDTC is administered to the mammal in a dose of 0.1 to 1000mg of PDTC per kg or body weight.